NOVOLOG MIX 70/30 FLEXPEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOVOLOG MIX 70/30 FLEXPEN (NOVOLOG MIX 70/30 FLEXPEN).
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It replaces endogenous insulin and has a faster onset and shorter duration than regular human insulin due to altered amino acid sequence (substitution of proline at position 28 with aspartic acid).
| Metabolism | Insulin aspart is metabolized primarily by insulin-degrading enzyme (IDE). |
| Excretion | Renal elimination of degradation products. Approximately 30-40% of insulin dose is excreted unchanged in urine; the remainder is metabolized primarily in liver and kidney and excreted as metabolites. |
| Half-life | 0.5-1 hour for the rapid-acting insulin aspart component and 8-10 hours for the protamine-crystallized insulin aspart component. Clinical context: biphasic profile allows for both prandial and basal coverage. |
| Protein binding | < 5% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Approximately 0.5-1 L/kg. Clinical meaning: reflects distribution into extracellular fluid and tissues. |
| Bioavailability | 60-80% after subcutaneous administration, with variability depending on injection site and technique. |
| Onset of Action | 10-20 minutes after subcutaneous injection. |
| Duration of Action | Up to 24 hours. Clinical note: the prolonged effect is due to the protamine-crystallized component; peak action occurs 1-4 hours after injection. |
Subcutaneous injection only. Initial total daily insulin dose: 0.5 to 1 unit/kg/day. Administer 70% intermediate-acting insulin aspart protamine and 30% rapid-acting insulin aspart. Typically given twice daily within 15 minutes before meals. Dose individualize based on glycemic goals.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-59 mL/min: Reduce dose by 25% and monitor glucose. GFR 15-29 mL/min: Reduce dose by 50%. GFR <15 mL/min: Reduce dose by 50% and consider further adjustment based on glucose levels. Use with caution due to increased risk of hypoglycemia. |
| Liver impairment | Child-Pugh Class A: No adjustment recommended. Child-Pugh Class B: Reduce dose by 25% and monitor glucose. Child-Pugh Class C: Reduce dose by 50% and titrate carefully due to impaired gluconeogenesis. |
| Pediatric use | For children aged 2-18 years: Individualize dose based on metabolic needs. Typical starting total daily dose: 0.5-1 unit/kg/day subcutaneously divided into two daily doses (before breakfast and dinner). Adjust based on blood glucose monitoring. Not studied in children under 2 years. |
| Geriatric use | Start with lower total daily dose (e.g., 0.2-0.4 unit/kg/day) due to increased risk of hypoglycemia. Titrate slowly. Monitor renal function and cognitive status. Avoid in frail elderly with poor nutritional intake. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NOVOLOG MIX 70/30 FLEXPEN (NOVOLOG MIX 70/30 FLEXPEN).
| Breastfeeding | Insulin aspart is a large protein molecule and is not excreted into breast milk in clinically significant amounts; no M/P ratio available. Insulin aspart is considered compatible with breastfeeding, but dose adjustments may be needed due to postpartum hormonal changes. |
| Teratogenic Risk | Insulin aspart is not teratogenic in animal studies; however, poor glycemic control increases risks of congenital anomalies, macrosomia, and neonatal hypoglycemia. First trimester: risk of malformations related to hyperglycemia, not insulin itself. Second and third trimesters: risk of fetal macrosomia, polyhydramnios, and neonatal hypoglycemia if maternal glucose not well-controlled. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to insulin aspart or any of its excipients.","During episodes of hypoglycemia."]
| Precautions | ["Hypoglycemia: most common adverse reaction; may be severe and life-threatening.","Never share a NovoLog Mix 70/30 FlexPen between patients, even if the needle is changed.","Changes in insulin strength, manufacturer, type, or method of administration should be made cautiously and under close medical supervision.","Hypokalemia: may occur if insulin dose is too high; monitor potassium levels in patients at risk.","Fluid retention and heart failure with concomitant use of thiazolidinediones (TZDs)."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose levels frequently, HbA1c every 1-2 months, fetal growth via ultrasonography, and assess for polyhydramnios. Monitor for neonatal hypoglycemia after delivery. |
| Fertility Effects | No direct effects on fertility reported. Poor glycemic control can cause menstrual irregularities and ovulatory dysfunction, potentially impairing fertility. |